IPO - Bionano Genomics, Inc.

Form Type: CORRESP

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000114036125000652

Filing Summary: Bionano Genomics, Inc. is requesting the Securities and Exchange Commission to accelerate the effectiveness of their Registration Statement on Form S-3 (File No. 333-284124) to become effective on January 10, 2025, at 4:30 p.m. Eastern Time. This request is made in accordance with Rule 461 under the Securities Act of 1933, as amended. Once the Registration Statement is effective, confirmation is requested from their outside counsel. The filing includes the signature of Jonathan Dixon, General Counsel and Secretary of Bionano Genomics, Inc.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-01-06

Corporate Action: Ipo

Type: New

Accession Number: 000114036125000291

Filing Summary: Bionano Genomics, Inc. is conducting a registered direct offering of certain securities, including 22,900,000 shares of common stock, 16,782,540 pre-funded warrants, and 39,682,540 purchase warrants. The offerings aim to raise net proceeds of approximately $9 million for general corporate purposes, research and development, repayment of existing debts, and capital expenditures. The placement agent, H.C. Wainwright & Co., is facilitating the sale and will receive specified fees. The pre-funded warrants are immediately exercisable at an exercise price of $0.001, while the purchase warrants will have an exercise price of $0.252 and are exercisable upon stockholder approval. The offering is expected to close on January 6, 2025, and shares will be listed under the Nasdaq symbol 'BNGO.' Details of the financial performance indicate a revenue of $22.6 million for the nine-month period ending September 30, 2024, representing an 11% decrease from the previous year. Considerations include significant risks related to market volatility and operational challenges. The document also references previous financial adjustments tied to a settlement agreement and the conversion price adjustments of existing debts.

Document Link: View Document